100% German Medical Cannabis from Demecan Now Available in Pharmacies

Demecan, Germany’s only independent medical cannabis producer (the other two are Aurora and Tilray), has prepared its first cannabis flowers for the German Federal Institute for Drugs and Medical Products (BfArM), constituting its first crop for German pharmacies.

In 2022, more than 300 kg of high-quality cannabis flowers have already been harvested, dried, and packaged by Demecan. The first batch of 100 kg will be collected by the German Cannabis Agency and distributed to pharmacies.

The company opted for a predominantly indica variety based on the OG Kush cultivar with a high THC content, between 18% and 22%. Since March, another variety (type 2 DEMECAN) is also in culture, without more details for the moment on the chosen variety, although we already know that it will have to make between 12 and 16% of THC with less than 1% CBD.

Demecan has already produced about half of the annual quantity ordered by the BfArM, and up to 660 kg of this variety are delivered each year from their growing site in Saxony.

For physician and co-founder Dr. Adrian Fischer, who is responsible for cultivation and quality control, the knowledge that his own cannabis flowers are available in pharmacies is a particularly important step: “At last, cannabis from Germany is available in pharmacies. I am particularly happy that this quality product can help many patients and that we can improve the supply situation through cultivation in this country. Of course, it would be nice if we could produce much more. Demecan is capable of doing that.

Stay informed with the latest affairs about the world of hemp. One potentially useful cannabis news tool is Hemp.im app and its companion marijuana news website.

Since 2017, German law has allowed medical cannabis

In 2019, Demecan was the only independent German company to win the federal government’s contract to produce medical cannabis flowers. The resulting supply contract is valid for a period of four years. The production takes place in their EU-GMP certified production site near Dresden and according to the quality standards of medicine manufacturing.

The 100,000 m² production site was acquired by Demecan in the summer of 2020. In less than 15 months of construction, the building – a former slaughterhouse – was transformed and is now the largest indoor cannabis production facility in Europe.

24 cm of reinforced concrete in all walls, steel doors, 150 cameras, and a high-tech computer system to control and optimize the growth of the plants, ensuring the perfect development of the plants. Thanks to its scalable production capacities, Demecan can also massively increase its production capacity, even at short notice, in order to meet the growing demand in Germany.

__

(Featured image by 7raysmarketing via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in NEWSWEED, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.